Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.

Journal of viral hepatitis - 1 Apr 2018

Bhardwaj N, Ragonnet-Cronin M, Murrell B, Chodavarapu K, Martin R, Chang S, Miller M D, Feld J J, Sulkowski M, Mangia A, Wertheim J O, Osinusi A, McNally J, Brainard D, Mo H, Svarovskaia E S

Abstract excerpt

Treatment with the direct-acting antiviral agent (DAA) sofosbuvir (SOF), an NS5B inhibitor, and velpatasvir (VEL), an NS5A inhibitor, demonstrates viral cure rates of ≥95% in hepatitis C virus (HCV) genotypes (GT) 1-6. Here, we investigated intrapatient HCV diversity in NS5A and NS5B using Shannon entropy to examine the relationship between viral diversity and treatment outcome. At baseline, HCV diversity was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Heterocyclic Compounds, 4 or More Rings

Share to Ribavirin

Share to Sofosbuvir

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 29112331
DOI: 10.1111/jvh.12825

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.PMID 29112331Read ↗

Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a.Semantic proximity Read ↗

Evidence for deleterious hepatitis C virus quasispecies mutation loads that differentiate the response patterns in IFN-based antiviral therapy.Semantic proximity Read ↗

Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy.Semantic proximity Read ↗

Intra-host evolutionary dynamics of the hepatitis C virus among people who inject drugs.Semantic proximity Read ↗

Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection.Semantic proximity Read ↗

Hepatitis C virus transmission bottlenecks analyzed by deep sequencing.Semantic proximity Read ↗

Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation RateSemantic proximity Read ↗

Baseline interpatient hepatitis B viral diversity differentiates HBsAg outcomes in patients treated with tenofovir disoproxil fumarate.Semantic proximity Read ↗

HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin.Semantic proximity Read ↗

Ultradeep pyrosequencing of NS3 to predict response to triple therapy with protease inhibitors in previously treated chronic hepatitis C patients.Semantic proximity Read ↗

Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy.Semantic proximity Read ↗

Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.